fda glp-1 compounded warning september 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

FDA cracks down on 'misleading' compounded GLP-1s by telehealth companies - Indianapolis News | Indiana Weather | Indiana Traffic

26.27

★★★★☆4.8 (126)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

21.36

★★★★★4.9 (98)

Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines

22.68

★★★★★5.0 (157)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

29.14

★★★★★4.7 (84)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

27.33

★★★★★4.9 (203)

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

27.91

★★★★★5.0 (176)

Fda Warning Letters Glp-1 Compounded September 2025 A company called Nomida has received an FDA

24.90

★★★★★4.8 (132)